vTv Therapeutics Inc. (VTVT)
Symbol Info
Listed Symbol VTVT
Name vTv Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $12,434,000
Latest Fiscal EPS $-0.72
Price Info
21 Day Moving Average $1.5255
21 Day EMA $1.474530
50 Day Moving Average $1.4192
50 Day EMA $1.456330
200 Day EMA $1.698670
200 Day Moving Average 1.757470
52 Week High $4.59
52 Week Low $1.00
52 Week Change $-56.047203
Alpha 0.036504
Beta -3.5511
Standard Deviation 0.400403
R2 0.100541
Periods 51
Share Information
10 Day Average Volume 164,174
20 Day Average Volume 400,232
30 Day Average Volume 413,568
50 Day Average Volume 334,566
Outstanding Shares 58,533,291
Float Shares 58,402,177
Percent Float 99.78%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 79
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 417,841
Institute Holdings Percent 10.300000
Institute Sold Previous 3 Months 126,711
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 5
Insider Holdings Percent 0.20%
Insider Sold Previous 3 Months -
Insiders Shares Owned 131,114
Price Change
7 Day Price Change $0.0250000
7 Day Percent Change 1.71%
21 Day Price Change $-0.08
21 Day Percent Change -5.10%
30 Day Price Change $0.0200000
30 Day Percent Change 1.36%
Month To Date Price Change $-0.06
Month To Date Percent -3.87%
90 Day Price Change $0.060000
90 Day Percent Change 4.20%
Quarter To Date $-0.06
Quarter To Date Percent -3.87%
180 Day Price Change $0.030000
180 Day Percent Change 2.05%
200 Day Price Change $-0.23
200 Day Percent Change -13.37%
Year To Date $-1.16
Year To Date Percent -43.77%
Profile
Description vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Details
Issue Type CS
Market Cap $87,214,604
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 58,533,291
CEO Stephen L. Holcombe
Employees 52
Last Audit UE
Classification
CIK 0001641489
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 4170 Mendenhall Oaks Parkway
High Point, NC 27265
Website http://www.vtvtherapeutics.com
Facisimile +1 336 841-0310
Telephone +1 336 841-0300
Email IR@vtvtherapeutics.com
Key Ratios
Profitability
EBIT Margin -99.4
EBITDA Margin -97.9
Pre-Tax Profit Margin -7,535.2
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $7,271,000
Revenue Per Share $0.2052
Revenue 3 Years $136.16
Revenue 5 Years $44.95
Valuation Measures
PE Ratio -
Enterprise Value $100,273,600
Price To Sales 7.262305
Price To Free Cash -5
PE High Last 5 Years -
Price To Book -
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -1.7
Financial Strength
Total Debt To Equity -
Int Coverage -3.9
Current Ratio 0.2
Leverage Ratio -0.1
Quick Ratio 0.2
Long Term Debt To Capital -
Assets
Receivables Turnover 1.2
Invoice Turnover -
Assets Turnover 0.20
Management Effectiveness
Return Assets -112.24
Return On Equity 18.75
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
VTVT
vTv Therap..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.